GSK2881078
Muscle Growth & Body CompositionAlso known as: GSK-2881078, GSK SARM
Mechanism
GSK2881078 is a non-steroidal SARM developed by GlaxoSmithKline for muscle wasting in COPD and other chronic conditions. It completed Phase 2 trials showing increased lean body mass with a manageable side effect profile, though development appears to have been deprioritized.
Technical detail
GSK2881078 is a non-steroidal SARM that entered Phase 2 clinical trials for chronic obstructive pulmonary disease (COPD)-associated muscle wasting. In healthy volunteer studies, it produced dose-dependent increases in lean body mass with expected suppression of total testosterone, SHBG, and HDL cholesterol. The Phase 2 COPD trial demonstrated modest improvements in appendicular lean mass. Adverse effects included dose-dependent HDL reduction and hepatic transaminase elevations. Development status is unclear following GlaxoSmithKline pipeline reprioritization.